Events
PhRMA hosts online and in-person events exploring science and policy issues that impact biopharmaceutical innovation and patient access to medicines. With members from the nation’s leading biopharmaceutical research companies, our events offer unique insights about the future of health in America.
The coronavirus pandemic continues to reshape our country and the world, particularly when it comes to challenging the perception of “what’s possible” in biopharmaceutical innovation. PhRMA recently sponsored STAT News' 2020 health summit convening leading health care CEOs, researchers, thought leaders, policymakers, physicians and health policy experts.
This virtual event launched the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections.
As part of a livestreamed three-part series, McClatchy is bringing together top-rated medical professionals, industry experts, patient advocates and policymakers to discuss the latest advancements to combat the virus. The first event’s focus will be innovation and treatment; McClatchy will explore from three perspectives how our country can accelerate research and innovation toward treatments for patients suffering from COVID-19. The following installments will focus on the path to a vaccine and the long-term impact of this crisis on health care policy.
The pandemic caused by the novel coronavirus has shut down countries around the world. STAT held a three-part digital event series that brought together experts to discuss one of society’s biggest hopes – that treatments or even vaccines can be developed. The audience was joined by executives from companies leading the way in developing treatments and they discussed current findings, clinical trials and efforts to expedite approvals as we face this global pandemic.
Baby Boomers face rising medical costs. At the same time, Medicare is growing, and taking up a greater share of the federal budget. While the Trump administration and Congress consider changes to Medicare, how can we keep costs in line, while also giving older Americans the care they need? The Atlantic gathered government officials, healthcare experts, and patient advocates to discuss the path forward for Medicare.
From 1990 to 2016, the share of women in the life sciences industry increased from 34 to 47 percent. Women also make up more than half of Ph.Ds. in biological and agricultural sciences. And many researchers are working to address health issues affecting women, ranging from endometriosis to heart conditions. Industry leaders, policymakers and academics have also shown how they’re dedicated to continuing to support innovation — and this includes fostering the next generation of scientists.
Medicine is improving at a breakneck pace; breakthroughs such as immunotherapy and genetics are changing the way we treat cancer. New drugs are being approved at an unprecedented rate while artificial intelligence and deep learning, until recently just science fiction, are actually starting to make a real difference in public health. The big question now: how can we take this kindling and set it ablaze?
Cancer isn’t as lethal as it once was, and yet more than 600,000 Americans are estimated to die from it this year alone, making this complex set of diseases the second leading cause of death in the country. But hope is rising: big data, immuno-oncology and once-in-a-generation medical advances have led to dramatic breakthroughs. New insights into the disease have pushed boundaries, with patients receiving uniquely personalized care.
How can Washington and the private sector work together to manage the cost of health care and deliver value to consumers? The two-part event will feature health care industry CEOs discussing the evolution of the pharmaceutical business model and a reevaluation of priorities including production of personalized medicines, R&D, and care for chronic diseases.
An estimated 5.7 million people in this country have Alzheimer’s. And the search for a treatment or a cure has not been promising. In the documentary, Turning Point, filmmaker James Keach, follows a team of scientists on the front lines of Alzheimer’s research and captures the disappointment and renewed hope of those working to disrupt the disease.
The history of Alzheimer’s research has been filled with setback after setback – in fact nearly every clinical trial has failed – but it is also one marked by perseverance and renewed hope. Advancements in medical imaging have increased our understanding of how the disease strikes, and efforts are underway to develop diagnostics to treat the disease before its onset.
How can scientists and researchers effectively engage with the public? Are vaccines a matter of personal choice or public health? What will the future of vaccines look like? The Atlantic gathered stakeholders from public health officials to the medical and scientific community to explore these questions at a forum in Philadelphia.
The Turning the Tide Against Cancer National Conference convened leaders from across the oncology community to explore the role of the patient across the continuum of cancer research and care and identify strategies that policymakers might consider to support meaningful patient engagement and deliver value to patients.